Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.

Studied

A randomized, double-blind phase 2 substudy in adults with type 2 diabetes compared retatrutide with placebo and dulaglutide. Its primary outcome was total fat-mass change measured by body-composition scans over 36 weeks.

Who / model

189 participants entered the body-composition substudy; 103 completed treatment and both scheduled scans.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Fat mass fell 15·2–26·1% in the higher retatrutide groups versus 4·5% with placebo and 2·6% with dulaglutide. The lowest retatrutide group did not significantly differ from placebo. Lean-mass loss as a proportion of weight loss resembled other obesity treatments. Gastrointestinal events were most common; serious adverse events occurred in some groups, with no deaths.

Limits

No author-stated limitations were available in the abstract. Only 103 of 189 participants completed treatment and paired scans.

Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary